In the analysis of NSCLC specimens, 92.3% of the patients demonstrated positive immunohistochemistry for LAG-3 and PD-1 dual expression, with 60% of the TILs co-expressing LAG-3 and PD-1 [248]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.